EA032917B1 - Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия - Google Patents

Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия

Info

Publication number
EA032917B1
EA032917B1 EA201390497A EA201390497A EA032917B1 EA 032917 B1 EA032917 B1 EA 032917B1 EA 201390497 A EA201390497 A EA 201390497A EA 201390497 A EA201390497 A EA 201390497A EA 032917 B1 EA032917 B1 EA 032917B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
disease
action
fatty liver
engineered polypeptides
Prior art date
Application number
EA201390497A
Other languages
English (en)
Russian (ru)
Other versions
EA201390497A1 (ru
Inventor
Мэри Эриксон
Дэвид С. Литзингер
Зиджиан Гуо
Джонатан Дэвид Рот
Сумитра С. Гхош
Original Assignee
Амилин Фармасьютикалс, Ллк
Астразенека Фармасьютикалс Лп
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амилин Фармасьютикалс, Ллк, Астразенека Фармасьютикалс Лп filed Critical Амилин Фармасьютикалс, Ллк
Publication of EA201390497A1 publication Critical patent/EA201390497A1/ru
Publication of EA032917B1 publication Critical patent/EA032917B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201390497A 2010-09-28 2011-09-28 Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия EA032917B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38740210P 2010-09-28 2010-09-28
US42209110P 2010-12-10 2010-12-10
PCT/US2011/053786 WO2012050930A2 (en) 2010-09-28 2011-09-28 Engineered polypeptides having enhanced duration of action

Publications (2)

Publication Number Publication Date
EA201390497A1 EA201390497A1 (ru) 2013-09-30
EA032917B1 true EA032917B1 (ru) 2019-08-30

Family

ID=45938879

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390497A EA032917B1 (ru) 2010-09-28 2011-09-28 Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
EA201390474A EA024507B1 (ru) 2010-09-28 2011-09-28 Хорошо растворимые лептины

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201390474A EA024507B1 (ru) 2010-09-28 2011-09-28 Хорошо растворимые лептины

Country Status (14)

Country Link
US (6) US20130274182A1 (https=)
EP (4) EP3305315A1 (https=)
JP (5) JP6174489B2 (https=)
CN (2) CN103547590B (https=)
BR (3) BR112013007385B1 (https=)
CA (3) CA3138758A1 (https=)
CY (2) CY1119023T1 (https=)
DK (3) DK2621519T3 (https=)
EA (2) EA032917B1 (https=)
ES (3) ES2630031T3 (https=)
MX (2) MX351128B (https=)
PL (1) PL3241558T3 (https=)
PT (2) PT2621519T (https=)
WO (2) WO2012050925A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
ES2732475T3 (es) * 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
CN111763247B (zh) * 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017020282A1 (zh) * 2015-08-05 2017-02-09 陕西麦科奥特科技有限公司 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
CA2998528A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016332352A1 (en) 2015-10-02 2018-04-12 Memorial Sloan-Kettering Cancer Center Small molecules blocking histone reader domains
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
EP3773461A4 (en) * 2018-04-13 2022-02-09 Massachusetts Institute of Technology TREATMENTS DESIGNED FOR HAIR REPAIR AND LONG-LASTING COLOR PRESERVATION
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
US20240391963A1 (en) * 2021-09-24 2024-11-28 The Uab Research Foundation Control of subunit stoichiometry in single-chain msp nanopores
US12466883B1 (en) * 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100255A2 (en) * 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US20100104588A1 (en) * 2002-06-28 2010-04-29 Dennis Mark S Serum albumin binding peptides for tumor targeting
US20100184641A1 (en) * 2003-09-19 2010-07-22 Novo Nordisk A/S Novel Plasma Protein Affinity Tags

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4695463A (en) 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
RU2212411C2 (ru) 1989-10-16 2003-09-20 Эмджен Инк. Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
CA2211656A1 (en) 1995-01-31 1996-08-08 Margret B. Basinski Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
AU4766596A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
JPH10513450A (ja) 1995-01-31 1998-12-22 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
WO1996031526A1 (en) 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
CA2218529A1 (en) 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
WO1996037517A1 (en) 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
CA2224867A1 (en) 1995-06-22 1997-01-09 Eli Lilly And Company Obesity protein intermediates and their preparation and use
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
JPH11508895A (ja) 1995-06-30 1999-08-03 イーライ・リリー・アンド・カンパニー 糖尿病を処置する方法
AU6688896A (en) 1995-08-17 1997-03-12 Amgen, Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997016550A1 (en) 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
WO1997018833A1 (en) 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997020933A2 (en) 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP2000505791A (ja) 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP0912609A2 (en) 1996-06-06 1999-05-06 Smithkline Beecham Plc Fragments of leptin (ob protein)
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
CZ90999A3 (cs) 1996-09-20 1999-06-16 Hoechst Aktiengesellschaft Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu
WO1998016545A1 (en) 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
WO1998024896A2 (en) 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein
WO1998028427A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
AU6569998A (en) * 1997-03-20 1998-10-12 Eli Lilly And Company Obesity protein formulations
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
ATE285415T1 (de) 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6538194B1 (en) 1998-05-29 2003-03-25 Catalysts & Chemicals Industries Co., Ltd. Photoelectric cell and process for producing metal oxide semiconductor film for use in photoelectric cell
JP4199421B2 (ja) 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
WO2000020872A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
ES2257287T3 (es) 1999-02-12 2006-08-01 Amgen Inc. Composiciones de leptina glicosiladas y metodos relacionados.
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
WO2001021647A2 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US7057015B1 (en) * 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU1303301A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
JP2001199887A (ja) 1999-11-10 2001-07-24 Takeda Chem Ind Ltd 体重増加抑制剤
US7157564B1 (en) 2000-04-06 2007-01-02 Affymetrix, Inc. Tag nucleic acids and probe arrays
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
KR20050084751A (ko) 2002-11-01 2005-08-29 가부시끼가이샤 도꾸야마 중합성 조성물, 그의 경화체의 제조법 및 광학 물품
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
US7898623B2 (en) 2005-07-04 2011-03-01 Semiconductor Energy Laboratory Co., Ltd. Display device, electronic device and method of driving display device
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
CA2647568A1 (en) 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CN102197049B (zh) 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
CN102292346B (zh) 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
RU2585231C2 (ru) * 2010-06-04 2016-05-27 Ск Кемикалз Ко., Лтд. Слитый белок, обладающий активностью фактора vii
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104588A1 (en) * 2002-06-28 2010-04-29 Dennis Mark S Serum albumin binding peptides for tumor targeting
US20100184641A1 (en) * 2003-09-19 2010-07-22 Novo Nordisk A/S Novel Plasma Protein Affinity Tags
WO2009100255A2 (en) * 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENNIS et al. Albumin Binding as a General Strategy for Improving the Pharmacokmetics of Proteins" JBC 2002, 277(38) 35035-35043 *

Also Published As

Publication number Publication date
EP2621515A4 (en) 2014-07-16
EP3241558B1 (en) 2021-03-03
JP2017081939A (ja) 2017-05-18
CN103547590A (zh) 2014-01-29
CA2813087C (en) 2020-07-21
US20160083446A1 (en) 2016-03-24
EP2621515A2 (en) 2013-08-07
BR112013007385A2 (pt) 2021-04-20
US20200362006A1 (en) 2020-11-19
US20160137709A1 (en) 2016-05-19
JP2013543497A (ja) 2013-12-05
WO2012050925A3 (en) 2012-07-05
MX2013003482A (es) 2013-10-25
US20230115655A1 (en) 2023-04-13
CY1119498T1 (el) 2018-03-07
EP2621519B1 (en) 2017-06-28
EP3241558A2 (en) 2017-11-08
DK2621515T3 (en) 2017-07-17
WO2012050930A2 (en) 2012-04-19
WO2012050930A3 (en) 2012-06-14
PL3241558T3 (pl) 2021-08-30
JP6412183B2 (ja) 2018-10-24
CY1119023T1 (el) 2018-01-10
JP2017141232A (ja) 2017-08-17
DK3241558T3 (da) 2021-04-26
ES2873253T3 (es) 2021-11-03
JP2020033366A (ja) 2020-03-05
JP6174489B2 (ja) 2017-08-02
EP3241558A3 (en) 2018-05-16
CA2813038A1 (en) 2012-04-19
EA201390474A1 (ru) 2013-07-30
CN103403019B (zh) 2016-10-12
US20130274182A1 (en) 2013-10-17
BR112013007388A2 (pt) 2020-10-06
EA201390497A1 (ru) 2013-09-30
US10087228B2 (en) 2018-10-02
JP6608799B2 (ja) 2019-11-20
WO2012050925A2 (en) 2012-04-19
EP3305315A1 (en) 2018-04-11
DK2621519T3 (en) 2017-10-16
BR122021020041B1 (pt) 2023-03-07
CA2813087A1 (en) 2012-04-19
CA2813038C (en) 2021-12-28
EP2621519A2 (en) 2013-08-07
EP2621519A4 (en) 2014-07-09
MX349054B (es) 2017-07-07
BR112013007385B1 (pt) 2022-07-26
US20130203661A1 (en) 2013-08-08
MX351128B (es) 2017-10-03
PT2621515T (pt) 2017-07-12
EA024507B1 (ru) 2016-09-30
PT2621519T (pt) 2017-10-04
MX2013003472A (es) 2013-10-30
ES2641869T3 (es) 2017-11-14
JP2014502252A (ja) 2014-01-30
CN103547590B (zh) 2017-11-28
CA3138758A1 (en) 2012-04-19
ES2630031T3 (es) 2017-08-17
CN103403019A (zh) 2013-11-20
EP2621515B1 (en) 2017-03-29
US11535659B2 (en) 2022-12-27
BR112013007388B1 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
EA032917B1 (ru) Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
WO2013009539A8 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
MX345245B (es) Polipeptidos manipulados que tienen duracion de accion incrementada.
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
WO2008021368A3 (en) Compositions and methods for neuroprotection
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
HK1208155A1 (en) Transmucosal delivery of engineered polypeptides
TN2009000124A1 (en) Injectable depot composition and its process of preparation
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
WO2010011439A3 (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
IN2015DN00376A (https=)
MX2012008603A (es) Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
WO2017123592A8 (en) Bacteria engineered to treat disorders associated with bile salts
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
TW200806293A (en) Methods of treatment with CETP inhibitors